

LISTING OF CLAIMS

Please cancel claims 11-14, 16, 17, 29-36, 49-52, 54, 55, 58-60, 66, 68-74 and 76 without prejudice to future prosecution. The following listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Previously presented) An isolated mammalian anti-Dengue virus antibody, comprising at least one variable region comprising the amino acid sequence set forth in SEQ ID NO: 4.

Claim 2. (Original) An antibody according to Claim 1, wherein said antibody binds Dengue virus NS-1 protein.

Claims 3-8. (Canceled)

Claim 9. (Previously presented) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising the amino acid sequence set forth in SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claims 10-14. (Canceled)

Claim 15. (Previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ IN NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar,

intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claims 16-18. (Canceled)

Claim 19. (Previously presented) An isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NO: 4 produced by a method comprising providing a host cell or a non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

Claim 20. (Previously presented) An isolated mammalian anti-Dengue virus antibody, comprising all of the light chain CDR sequences of SEQ ID NO: 4.

Claim 21. (Canceled)

Claim 22. (Original) A Dengue virus antibody according to Claim 20, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claims 23-27. (Canceled)

Claim 28. (Previously presented) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having all of the light chain CDR sequences of SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claims 29-37. (Canceled)

Claim 38. (Previously presented) An isolated mammalian anti-Dengue virus antibody having all of the light chain CDR sequences of SEQ ID NO: 4 produced by a method comprising providing a host cell or a non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts nucleic acid molecules encoding said antibody.

Claim 39. (Previously presented) An isolated mammalian anti-Dengue virus antibody, comprising at least one light chain CDR shown in SEQ ID NO: 4.

Claim 40. (Canceled)

Claim 41. (Original) A Dengue virus antibody according to Claim 39, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claims 42-46. (Canceled)

Claim 47. (Previously presented) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one light chain CDR shown in SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claims 48-52. (Canceled)

Claim 53. (Previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one light chain CDR shown in SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode

selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claims 54-56. (Canceled)

Claim 57. (Previously presented) An isolated mammalian anti-Dengue virus antibody having at least one light chain CDR shown in SEQ ID NO: 4 produced by a method comprising providing a host cell or a non-human transgenic animal or transgenic plant or plant cell capable of expressing a nucleic acid molecule encoding said antibody in recoverable amounts wherein said nucleic acid molecule comprises SEQ ID NO: 2.

Claims 58-95. (Canceled)